Dr. Joshua Hornig, an Otolaryngologist, explains a new technique, endoscopic parathyroid surgery that is used at MUSC to remove the thyroid or thyroid cancer. This innovative surgery leaves only a half inch incision, as opposed to a 4 inch incision by standard thyroid surgery. Dr. Hornig talks about the instrumentation used, what thyroid conditions are treated and how quickly a patient will recover with almost no visible scarring.
Dr. Joshua Hornig, an Otolaryngologist, explains a new technique, endoscopic parathyroid surgery that is used at MUSC to remove the thyroid or thyroid cancer. This innovative surgery leaves only a half inch incision, as opposed to a 4 inch incision by standard thyroid surgery. Dr. Hornig talks about the instrumentation used, what thyroid conditions are treated and how quickly a patient will recover with almost no visible scarring.
Nephrotic syndrome can be a part of diabetic kidney disease. Kidney disease specialist, Dr. Florence Hutchison, talks in detail about the condition, new treatments offered, medications to reduce the common symptoms such as swelling and high blood pressure.
Nephrotic syndrome can be a part of diabetic kidney disease. Kidney disease specialist, Dr. Florence Hutchison, talks in detail about the condition, new treatments offered, medications to reduce the common symptoms such as swelling and high blood pressure.
Nephrotic syndrome is a condition often characterized by very high levels of protein in the urine and can be caused by diabetes. Dr. Florence Hutchison, a nephrologist (kidney disease specialist), explains how diabetes can be a cause for nephritic syndrome, what the symptoms are and how to treat the condition.
Nephrotic syndrome is a condition often characterized by very high levels of protein in the urine and can be caused by diabetes. Dr. Florence Hutchison, a nephrologist (kidney disease specialist), explains how diabetes can be a cause for nephritic syndrome, what the symptoms are and how to treat the condition.
In this CME activity, an expert in the management of type 2 diabetes discusses recent data on current and emerging glucagon-like peptide (GLP-1) mimetics and dipeptidyl peptidase IV (DPP-IV) inhibitors.
Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file.